Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 7(1): 157, 2017 03 13.
Artículo en Inglés | MEDLINE | ID: mdl-28279017

RESUMEN

Herbicides have long-term effects on the vegetative parts and reproduction of plants; however, the carry-over effects of herbicides on the F1 generation of invasive plants remain unclear. The objectives of this work were to investigate the germination and growth of the F1 generation of A. retroflexus, an invasion plant, treated by sublethal herbicides. The results demonstrated that atrazine or tribenuron-methyl had carry-over effects on the F1 generation of A. retroflexus. Atrazine or tribenuron-methyl exposure during the vegetative and reproductive periods significantly inhibited the germination and growth of the F1 generation; a lower sublethal dose of atrazine or tribenuron-methyl did not weaken the inhibition of germination or growth of the F1 generation. Our results suggest that although herbicides have a carry-over inhibition effect on the F1 generation of invasive plants, they may have a more serious carry-over effect on native plants and cause changes in weed species composition and weed diversity.


Asunto(s)
Amaranthus/fisiología , Germinación/efectos de los fármacos , Herbicidas/efectos adversos , Plantones/crecimiento & desarrollo , Amaranthus/efectos de los fármacos , Arilsulfonatos/efectos adversos , Atrazina/efectos adversos , Especies Introducidas , Plantones/efectos de los fármacos
2.
J Am Assoc Nurse Pract ; 29(2): 104-115, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28139897

RESUMEN

PURPOSE: We review the use of oral antiplatelet (OAP) therapies in acute coronary syndrome (ACS) management for nurse practitioners (NPs), focusing on current guideline recommendations. DATA SOURCES: Treatment guidelines and clinical articles from PubMed. CONCLUSIONS: Guidelines recommend that dual antiplatelet therapy with a P2Y12 inhibitor and aspirin be initiated for ACS management. The P2Y12 inhibitor clopidogrel has established efficacy, but is associated with suboptimal and delayed platelet inhibition and variability in response. The newer P2Y12 inhibitors prasugrel and ticagrelor have demonstrated superior efficacy outcomes versus clopidogrel. Consequently, non-ST-segment elevation ACS (NSTE-ACS) guidelines now recommend that ticagrelor be used in preference to clopidogrel for patients treated with stents or managed medically. Because of their higher potency, prasugrel and ticagrelor are associated with increased bleeding rates versus clopidogrel, but with no increased risk of severe or life-threatening bleeding. Guidelines recommend dual antiplatelet therapy be continued ≥12 months in both medically managed and stented ACS patients, and in some cases beyond this, in absence of high bleeding risk. Updated guidelines assign preference to ticagrelor over clopidogrel for maintenance therapy in patients with NSTE-ACS and ST-elevation myocardial infarction. IMPLICATIONS FOR PRACTICE: Enhanced NP understanding of OAP agents and current guidelines could contribute to improved ACS patient management.


Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Administración Oral , Manejo de la Enfermedad , Inhibidores de Agregación Plaquetaria/uso terapéutico , Adenosina/efectos adversos , Adenosina/análogos & derivados , Adenosina/uso terapéutico , Arilsulfonatos/efectos adversos , Arilsulfonatos/uso terapéutico , Aspirina/efectos adversos , Aspirina/uso terapéutico , Clopidogrel , Humanos , Enfermeras Practicantes , Inhibidores de Agregación Plaquetaria/efectos adversos , Clorhidrato de Prasugrel/efectos adversos , Clorhidrato de Prasugrel/uso terapéutico , Ticagrelor , Ticlopidina/efectos adversos , Ticlopidina/análogos & derivados , Ticlopidina/uso terapéutico
3.
Asian Pac J Allergy Immunol ; 29(2): 134-42, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21980828

RESUMEN

BACKGROUND AND OBJECTIVE: Suplatast tosilate is a Th2 cytokine inhibitor that is effective for controlling persistent asthma. However, the long-term efficacy of suplatast is unknown. We compared the clinical efficacy of long-term monotherapy with suplatast tosilate with a low dose of inhaled steroids in patients with mild atopic asthma. METHODS: A total of 32 patients with mild atopic asthma were randomly assigned to receive suplatast (n=15) or fluticasone (n=17). In the suplatast group, 100 mg of suplatast was given orally 3 times a day (total daily dose = 300 mg) for 2 years. In the fluticasone group, 100 pg of fluticasone was inhaled twice a day (total daily dose = 200 tg) for 2 years. RESULTS: In the suplatast group, the improvements in peak expiratory flow (PEF) rate and forced expiratory volume in 1 second (FEV1) and the changes in the symptom diary scale and frequency of beta2 stimulant inhalation were generally similar to those in the fluticasone group, and efficacy was maintained for 2 years. Improvements in inflammatory indices, such as the sputum eosinophil cationic protein (ECP) level and exhaled nitric oxide concentration, were comparable in the suplatast and fluticasone groups. The improvement in airway hyperresponsiveness was also similar in the 2 groups. The peripheral blood eosinophil percent change, serum ECP level, and total IgE antibody titer improved only in the suplatast group. CONCLUSIONS: Long-term treatment with suplatast significantly improved symptoms and inflammatory indices in patients with mild atopic asthma. Along with fluticasone, suplatast is considered a useful drug for the management of mild atopic asthma.


Asunto(s)
Androstadienos/administración & dosificación , Arilsulfonatos/administración & dosificación , Asma/tratamiento farmacológico , Compuestos de Sulfonio/administración & dosificación , Administración por Inhalación , Adulto , Anciano , Anciano de 80 o más Años , Androstadienos/efectos adversos , Arilsulfonatos/efectos adversos , Asma/diagnóstico , Asma/fisiopatología , Progresión de la Enfermedad , Cálculo de Dosificación de Drogas , Femenino , Fluticasona , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Pruebas de Función Respiratoria , Compuestos de Sulfonio/efectos adversos , Resultado del Tratamiento
4.
J Asthma ; 42(7): 567-70, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16169790

RESUMEN

Suplatast tosilate is an antiallergic drug that selectively suppresses Th2-cytokine production and inhibits airway hyperresponsiveness and eosinophilic airway inflammation. This drug has been also shown to improve pulmonary function and symptoms in steroid-dependent asthma, resulting in a decrease in doses of inhaled corticosteroid. However, the precise mechanism by which suplatast tosilate exerts an antiasthmatic effect in vivo remains to be known. Our previous study showed the polarization of circulating type 1 dendritic cells (DC1)/type 2 dendritic cells (DC2) balance toward DC2 in asthma, which might be associated with its Th2-dominant immune response. In the present study, we attempted to clarify the effect of suplatast tosilate on DC1/DC2 balance in asthma. Using multicolor flow cytometry, we enumerated circulating DC1 and DC2 before and 8 weeks after treatment with suplatast tosilate in nine patients with asthma. Before the treatment, the patients with asthma had a significant higher percentage of DC2 together with a significant lower ratio of DC1/DC2 compared with normal subjects. Administration of suplatast tosilate significantly decreased the percentage of DC2, but not that of DC1, resulting in a significant raises of the ratio of DC1/DC2. Concomitantly, intracellular cytokine analysis showed that the percentage of IL-4 producing CD4+ T cells was significantly decreased after the treatment. These data suggest that suplatast tosilate normalizes the polarized DC1/DC2 balance toward DC2 in asthma, which may also alter its Th2-dominant Th1/Th2 balance toward Th1.


Asunto(s)
Antialérgicos/uso terapéutico , Células Presentadoras de Antígenos/efectos de los fármacos , Arilsulfonatos/uso terapéutico , Asma/tratamiento farmacológico , Células Dendríticas/efectos de los fármacos , Antagonistas de los Receptores Histamínicos/uso terapéutico , Compuestos de Sulfonio/uso terapéutico , Corticoesteroides/administración & dosificación , Anciano , Antialérgicos/efectos adversos , Arilsulfonatos/efectos adversos , Asma/inmunología , Recuento de Células Sanguíneas , Hiperreactividad Bronquial/sangre , Hiperreactividad Bronquial/tratamiento farmacológico , Células Dendríticas/clasificación , Células Dendríticas/inmunología , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Volumen Espiratorio Forzado/efectos de los fármacos , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Antagonistas de los Receptores Histamínicos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Compuestos de Sulfonio/efectos adversos , Resultado del Tratamiento
5.
Oral Dis ; 9(5): 273-6, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14628896

RESUMEN

OBJECTIVE: The purpose of this report is to document the presence of dimethyl sulfide in mouth air as the predominant volatile sulfur compound (VSC) in an asthmatic patient who was regularly taking suplatast tosilate. STUDY DESIGN: The patient was a 33-year-old woman who complained of bad breath. She had been diagnosed as having asthma and was receiving periodical medical examinations once a month. VSC in her mouth air were measured with a gas chromatograph. Oral physiotherapy was also carried out to remove any oral malodor of which the source was intraoral. RESULTS: With the improvement in oral hygiene and periodontal conditions, the level of VSC was reduced but dimethyl sulfide still remained as the predominant VSC. CONCLUSIONS: Dimethyl sulfide metabolized from suplatast tosilate may be a potential cause of halitosis.


Asunto(s)
Antiasmáticos/efectos adversos , Halitosis/inducido químicamente , Adulto , Arilsulfonatos/efectos adversos , Asma/tratamiento farmacológico , Cromatografía de Gases , Femenino , Halitosis/metabolismo , Humanos , Sulfuros/análisis , Compuestos de Sulfonio/efectos adversos
6.
J Environ Biol ; 23(4): 353-8, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12674373

RESUMEN

The presence of chlorimuron ethyl and metsulfuron methyl in two soils was determined by a modified petri dish bioassay. Pregerminated seeds of maize and sunflower were placed in petri dishes containing 85 to 100 g of treated soil. Radicle root lengths were measured after 24 h. Chlorimuron had no effect on maize on the Balcarce soil, however 0.007 microg g(-1) decreased sunflower root length. Chlorimuron decreased maize and sunflower root length regardless application dose on the San Cayetano soil. Metsulfuron decreased maize root length at 0.04 microg g(-1) and sunflower at 0.021 microg g(-1) on the Balcarce soil. On the San Cayetano soil metsulfuron at 0.001 microg g(-1) decreased maize and sunflower root length. The phytotoxicity of chlorimuron and metsulfuron changed according to soil type and dose. Maize and sunflower were 1.3-1.5 and 1.3-1.8 times respectively more sensitive to chlorimuron on the San Cayetano soil than on the Balcarce soil. In the case of metsulfuron, maize was similarly sensitive on both soils but sunflower was 1.7-2.0 times more sensitive on the San Cayetano soil than on the Balcarce soil. Phytotoxicity increased as organic matter (OM) content decreased and/or when the soil pH and concentration increased.


Asunto(s)
Arilsulfonatos/análisis , Residuos de Plaguicidas/análisis , Pirimidinas/análisis , Contaminantes del Suelo/análisis , Compuestos de Sulfonilurea/análisis , Argentina , Arilsulfonatos/efectos adversos , Bioensayo/métodos , Helianthus/crecimiento & desarrollo , Residuos de Plaguicidas/efectos adversos , Pirimidinas/efectos adversos , Semillas/crecimiento & desarrollo , Contaminantes del Suelo/efectos adversos , Compuestos de Sulfonilurea/efectos adversos , Zea mays/crecimiento & desarrollo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...